Alejandro Díez-Vidal

Alejandro Díez-Vidal

Auto-generated profile, based on publicly available information

Alejandro Díez-Vidal

Infectious Diseases Unit, Department of Internal Medicine, La Paz University Hospital, Madrid, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ADAlejandro Díez-Vidal
Alejandro Díez-Vidal
PMPatricia Martínez-Martín
Patricia Martínez-Martín
BGBorja González-Muñoz
Borja González-Muñoz
YTYale Tung-Chen
Yale Tung-Chen
Point-of-care ultrasound (POCUS) is a safe, noninvasive technique performed at the patient's bedside, providing immediate results to the operator. It complements physical examination and facilitates clinical decision-making. In infectious diseases, POCUS is particularly valuable, offering an initial assessment in cases of suspected infection. It often leads to an early tentative diagnosis enabling the prompt initiation of antimicrobial treatment without the delay associated with traditional radiology. POCUS provides direct visualization of affected organs, assists in evaluating fluid balance, and facilitates various interventions, all while reducing patient discomfort. For infectious disease specialists, becoming proficient in POCUS is a critical future challenge, requiring dedicated training for effective utilization.

18 April 2026 in eClinicalMedicine
Verified
Journal Article
Open access
CMCristina Marcelo-Calvo
Cristina Marcelo-Calvo
AEAndrés Esteban-Cantos
Andrés Esteban-Cantos
FJFrancisco Jurado
Francisco Jurado
RMRocío Montejano
Rocío Montejano
JRJavier Rodríguez-Centeno
Javier Rodríguez-Centeno
JAJosé R. Arribas
José R. Arribas
Metformin is increasingly studied as a potential geroprotective agent in the general population. We aimed to test the efficacy and safety of metformin to improve epigenetic age in older, well-controlled, non-diabetic people living with HIV. METFORAGING was a single-centre, double-blind, randomised, parallel-group, placebo-controlled pilot trial. Non-diabetic participants living with HIV who were aged 50 years or older, virologically suppressed, on a stable antiretroviral regimen with undetectable viral load for at least 12 months, and had CD4+ T-cell counts >500 cells/μL were recruited from the HIV clinic at La Paz University Hospital (Madrid, Spain). Participants were randomly assigned (1:1) to receive 850 mg oral metformin or matching placebo twice a day for 96 weeks. Participants, investigators, and outcome assessors were masked to treatment allocation. Study visits were conducted at baseline and at weeks 4, 8, 24, 48, 72, and 96. Adherence was evaluated at each visit through pill count and self-report. At baseline and week 96, whole-blood samples were used to calculate biological age across 11 epigenetic biomarkers: first-generation epigenetic clocks (Horvath’s clock and Hannum’s clock), second-generation epigenetic clocks (PhenoAge and GrimAge V2), principal component-derived epigenetic clocks (PC-Horvath, PC-Hannum, PC-PhenoAge and PC-GrimAge), a third-generation clock (DunedinPACE), and the DNA methylation-based estimator of blood telomere length (DNAmTL). The primary outcome was the adjusted between-group difference in epigenetic age acceleration (EAA) change measured by the PhenoAge clock at week 96 in the per-protocol population. Analyses were stratified by age, sex, baseline CD4 count, smoking status, statin treatment, and route of HIV transmission. The trial was registered with EudraCT, 2021-003299-15. Between March 2, and Oct 2, 2022, 55 individuals were screened, and 40 were randomly assigned to metformin (n = 19) or placebo (n = 21). Enrolment was closed at 40 participants because of slow recruitment, below the pragmatic target of 60 outlined in the study protocol. Median age was 56.4 years (IQR 53.0–60.8), 12 (30%) were female, and 35 (87.5%) self-identified as White. Mean adherence by pill count was 97.5% in both groups. 35 (87.5%) of 40 participants continued treatment to 96 weeks (n = 17 in the metformin group and n = 18 in the placebo group; per-protocol population). At week 96, the adjusted between-group difference (metformin vs. placebo) for PhenoAge EAA was −1.02 years (95% confidence interval [CI] −5.30 to 3.26; p = 0.627). 48 adverse events occurred in 16 (84%) of 19 participants who received metformin and 48 adverse events occurred in 19 (90%) of 21 participants who received placebo. In the metformin group, no serious adverse events were attributed to the medication and no deaths or hospitalisation occurred. Although no significant difference was noted in the primary outcome between groups, these preliminary findings support the feasibility of geroscience-trials in this population and support further investigation of metformin in larger, adequately powered studies to determine whether metformin can modify biological ageing in people with HIV. Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, and the European Union.

30 September 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PMPatricia Martínez-Martín
Patricia Martínez-Martín
AEAndrés Esteban-Cantos
Andrés Esteban-Cantos
FJFrancisco Jurado
Francisco Jurado
RMRocío Montejano
Rocío Montejano
LGLucía Gutiérrez-García
Lucía Gutiérrez-García
JAJosé R. Arribas
José R. Arribas
Background: Epigenetic age acceleration (EAA) predicts morbidity and mortality in the general population, but its prognostic utility in people with human immunodeficiency virus (HIV) (PWH) on suppressive antiretroviral therapy remains unclear. Methods: Longitudinal observational cohort of 216 PWH with sustained virological suppression (median 6.5 years) recruited from the DUAL-GESIDA trial and La Paz Aging Cohort (Spain). Baseline blood DNA methylation was assessed to evaluate 8 epigenetic clocks, their principal-component (PC) derivatives, and the telomere length estimator. Over 10 years, we recorded AIDS, serious non-AIDS (SNAEs), and aging-related events. Associations between EAA and outcomes were evaluated by multivariate Cox models. Results: One hundred five participants experienced ≥ 1 event, 162 events recorded in total (1 AIDS event, 65 SNAEs, and 96 aging-related events). A positive EAA by Horvath's clock was associated with a 50% higher risk of aging-related events. Participants with positive EAA according to PC-GrimAge, GrimAge V1-V2, as well as Hannum´s clock experienced more than 2-fold increased risk of SNAEs. Positive EAA by PC-GrimAge and PhenoAge was associated with an increased risk of non-AIDS cancer. Additionally, positive EAA according to GrimAge V1-V2 was linked to a 4-fold increase in all-cause mortality risk. All individuals who died (n = 17) had a baseline DunedinPACE value >1. No associations were found for the composite endpoint or cardiovascular events. Conclusions: In this preliminary study, GrimAge and PC-GrimAge were associated with increased risk of adverse outcomes in people with well-controlled HIV infection. These findings suggest their potential as long-term health-risk biomarkers, warranting validation in larger cohorts.

16 March 2024 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
ADAlejandro Díez-Vidal
Alejandro Díez-Vidal
JLJavier Gómez López
Javier Gómez López
PFPablo Rodríguez Fuertes
Pablo Rodríguez Fuertes
FJFabián Tejeda Jurado
Fabián Tejeda Jurado
PEPaula Berrocal Espinosa
Paula Berrocal Espinosa
YTYale Tung-Chen
Yale Tung-Chen

11 December 2025 in BMJ
Verified
Journal Article
Open access
ADAlejandro Díez-Vidal
Alejandro Díez-Vidal
JAJosé R. Arribas
José R. Arribas
Objective: To quantify the time lag between biomedical articles and the studies they describe as “recent,” a term widely used to imply timeliness despite rarely reflecting the actual age of the cited evidence. Design: Retrospective analysis of suspiciously timeless citations based on a structured PubMed search of 20 predefined “recent” expressions. Sample: 1000 English language, full text biomedical articles in which a “recent” expression is directly linked to a citation. Main outcome measure: Time lag in years between citing articles and their referenced “recent” studies. Results: The age of the cited “recent” studies varied widely. The citation lag ranged from 0 to 37 years (mean 5.53 years, median 4 years, interquartile range 2-7). The most frequent lag was one year (n=159, 15.9%), and 177 references (17.7%) were at least 10 years old. Citation patterns varied across medical specialties: critical care, infectious diseases, genetics, immunology, and radiology showed shorter median lags (around two years), while nephrology, veterinary medicine, and dentistry displayed substantially longer lags (ranging from 8.5 to 14 years). Among expressions, “recent approach,” “recent discovery,” and “recent study” were linked to older references, whereas “recent publication” and “recent article” had much fresher citations. The citation lag was similar across world regions and gradually decreased over time, with the most recent publications showing the shortest lags. Journals with high impact factors (≥12) cited more up-to-date work. Conclusions: This playful analysis suggests that “recent” is applied with striking elasticity across biomedical literature. While some authors cite genuinely recent work, others stretch the definition to decades. Readers and reviewers should take “recent” claims with a grain of chronological salt.

20 December 2023 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
AVAlejandro Díez Vidal
Alejandro Díez Vidal
JLJavier Gómez López
Javier Gómez López
MNMaría Angélica Rivera Núñez
María Angélica Rivera Núñez
AVAna María Martínez Virto
Ana María Martínez Virto
YCYale Tung Chen
Yale Tung Chen